Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Iptacopan in Patients With Generalized Myasthenia Gravis (gMG), Followed by an Open ...

A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment with the product. By reporting side effects ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

On this page, you can find our annual reporting documents and other disclosures, as well as many of our internal policies, codes, guidelines and commitments.

View recent presentations and learn more about upcoming events.

Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our corporate responsibility activities.

The Novartis Singapore site is their first biologics production facility in Asia and one of the largest biologics manufacturing investments in Singapore. It is aimed to launch and produce innovative ...

Learn about Novartis annual results, including media releases, annual reports, webcasts and presentations, and year-to-date figures.

Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction 1 Leqvio provides effective and sustained LDL-C ...